**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 54092

**Manuscript Type:** MINIREVIEWS

**Bone disease in chronic pancreatitis**

Ahmed A *et al*. Bone disease

Awais Ahmed, Aman Deep, Darshan J Kothari, Sunil G Sheth

**Awais Ahmed, Aman Deep**, **Sunil G Sheth**,Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States

**Darshan J Kothari**, Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, United States

**Author contributions**: Ahmed A and Deep A collected relevant data and literature, drafted the manuscript; Kothari DJ and Sheth SG conceptualized the review, made critical revisions related to important intellectual content of the manuscript; and approved final version of manuscript for submission.

**Corresponding author: Awais Ahmed, MD, Academic Fellow, Doctor,** Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, United States. aahmed1@bidmc.harvard.edu

**Received:** January 8, 2020

**Revised:** March 26, 2020

**Accepted:** April 18, 2020

**Published online:**

**Abstract**

Bone disease (osteopenia or osteoporosis) is a highly prevalent condition in society and presents a tremendous, preventable public health burden. Screening procedures, such as, dual-energy X-ray absorptiometry scans, have allowed early identification and intervention to improve bone health, and reduce the risk of osteoporotic fractures, which carry significant morbidity and mortality. The association of bone disease has been recognized in several diseases of the gastrointestinal tract, resulting in established guidelines for screening in patients with malabsorptive disorders such as inflammatory bowel disease and celiac disease. Increasingly, the risk of bone disease has been recognized in patients with chronic pancreatitis (CP), who share similar risk factors as patients with other high gastrointestinal disorders. As a result, there have been a number of studies examining the prevalence and risks of bone disease and fractures in patients with CP. This review aims to summarize the recent literature and current recommendations related to bone disease in CP.

**Key words:** Bone disease; Osteopenia; Osteoporosis; Fracture risk; Chronic pancreatitis; Malabsorption

Ahmed A, Deep A, Kothari DJ, Sheth SG. Bone disease in chronic pancreatitis. *World J Clin Cases* 2020; In press

**Core tip:** Bone disease is prevalent in chronic pancreatitis. Routine assessment of risk factors and a baseline dual-energy X-ray absorptiometry to evaluate bone density is recommended for these patients to reduce the risk of fractures in this patient population.

**INTRODUCTION**

Osteoporosis affects an estimated 75 million people across the United States, Europe and Japan[1]. Globally, 8.9 million osteoporotic fractures occur annually and are associated with increased morbidity and mortality[2]. Screening programs for prevention of osteoporotic fractures are cost-effective in reducing the incidence of new fractures, thus highlighting the importance of identifying risk factors that predispose to bone disease[3,4]. Bone health is maintained by a complex balance between bone formation and resorption, modulated by endocrine, immune and digestive organ systems, which in turn are affected by individual risk factors including age, gender, body mass index (BMI), nutritional status, tobacco and alcohol use, and chronic steroid use[5,6]. Chronic inflammatory conditions, especially those affecting the gastrointestinal tract, further increase the risk for bone disease, disrupting normal organ function as evidenced by the increased prevalence in patients with inflammatory bowel disease, celiac disease and chronic liver disease[7-11]. Chronic pancreatitis (CP) is a progressive and irreversible inflammatory condition, which results in exocrine and endocrine dysfunction. Thus, patients with CP are increasingly being recognized to be at higher risk for bone disease[12]. Our review summarizes the risk factors and prevalence of bone disease in CP.

**EPIDEMIOLOGY**

The prevalence of osteopenia in CP has been reported in studies to be anywhere between 18%-71.4%, with varying risk factors as previously described[13-15]. In a meta-analysis of by Duggan *et al*[14] 40% of the pooled patient population were found to have osteopenia. Furthermore, 25% were found to have osteoporosis. Similarly, in the multicenter European study, 42.18% of patients had osteopenia while 21.8% had osteoporosis[13]. In these studies, the patient population comprised mainly of adult non menopausal patients, with variable etiologies of CP. Common secondary risk factors for bone disease included tobacco and alcohol use, exocrine insufficiency and BMI.

**RISK FACTORS**

While the precise pathophysiology and mechanistic pathway of bone disease in CP is not well defined, presence of bone disease in other malabsorptive conditions of the gut, such as inflammatory bowel disease and celiac disease, has helped advance our understanding of risk factors and prevalence in CP[6-8,10]. Specifically, malabsorption of nutrients (Vitamin D and calcium), low bone mass, alcohol use, smoking and circulation of pro-inflammatory cytokines contribute to a decline in bone health in these patients, all of which can be seen in patients with CP (Table 1). Consequently, several studies have examined the risk factors and prevalence of bone disease in CP.

***Chronic inflammation***

Proinflammatory cytokines such as interleukin-6 (IL-6) increase bone turnover by perpetuating osteoclastic activity[16-18]. Similar associations have been made with systemic inflammation marker C-reactive protein (CRP) and bone disease[19,20]. This association of inflammation with low bone mineral density (BMD) and high bone turnover was demonstrated in patients with CP by Duggan *et al*[21] in 2015. In this study, patients with CP had an elevated mean high-sensitivity CRP [3.15 (1.3-7.75) *vs* 0.9 (0.5-2.15), *P* < 0.0013] and IL-6 [5.61 *vs* 2.58 (-0.06-1.82), *P* = 0.06], when compared to controls although the latter did not reach statistical significance. Both CRP and IL-6 were associated with low BMD. Notably, the study also analyzed markers of bone turnover, as a measure of bone metabolism. Compared to controls, markers of osteoblastic activity (procollagen 1 amino-terminal propeptide and osteocalcin) and osteoclastic activity (carboxy-terminal telopeptide of type 1 collagen) were significantly elevated in CP. Thus, demonstrating increased bone remodeling in the inflammatory state of CP.

***BMI***

In the general population, lower BMI is a risk factor for bone fracture. Patients with CP are at risk for being malnourished and thus may have a lower BMI, due to exocrine insufficiency, malabsorption, and ongoing alcohol and tobacco use[22-25]. Stigliano *et al*[13] showed in their study that mean BMI was lower in patients with CP and either osteopenia or osteoporosis (24 ± 3 and 22 ± 3, respectively) *vs* controls (25 ± 4) for both males and females (*P* = 0.001). These findings confirmed data from prior studies[26-29].

***Exocrine pancreatic insufficiency***

Exocrine pancreatic insufficiency (EPI)results from progressive destruction of acinar and ductal cells, leading to reduction in pancreatic enzyme and bicarbonate secretion and ultimately maldigestion and malabsorption. If left untreated, patients can present with steatorrhea, weight loss and, nutrient deficiency[29,30]. Although imperfect, diagnosis of EPI typically requires stool collection for fat quantification and/or fecal elastase concentration. Studies have evaluated EPI by measuring fecal elastase concentration or 72 h-stool fat quantification as a risk factor for developing osteopenia or osteoporosis, and have produced conflicting results[14]. In a multicenter, cross-sectional European study, Stigliano *et al*[13] used fecal elastase levels as a means of diagnosis of EPI, and did not find a correlation between presence of EPI and osteopenia or osteoporosis. Interestingly however, Haas *et al*[15], in their prospective cohort study of 50 male patients, noted that patients with EPI receiving pancreatic enzyme replacement therapy had higher bone density scores compared to those who were not taking pancreatic enzymes ( -0.80 ± 0.6 *vs* -1.51 ± 0.55, *P* < 0.05). Despite the discrepancy, screening for and treating EPI to prevent bone disease is recommended by pancreas experts[31-33].

***Nutritional deficiency***

The role of vitamin D, calcium and phosphorus is well established in bone homeostasis. Adequate vitamin D is essential for efficient and maximal absorption of intestinal calcium and phosphorus[34-37]. Vitamin D deficiency causes decreased intestinal calcium absorption which can lead to secondary hyperparathyroidism, which in turn stimulates osteoclastic demineralization of bone, resulting in osteopenia and osteoporosis. With primary sources of Vitamin D being sunlight exposure and diet, patients with CP are a particularly vulnerable group, as they are susceptible to malabsorption of fat soluble vitamins in EPI. However, studies to date have not consistently shown an association between vitamin D and low BMD or as a predictor of bone disease[13,27,28-29]. In one meta-analysis of nine studies, Hoogenboom *et al*[38] showed that while the pooled prevalence of vitamin D deficiency in CP patients was 65%, it was not significantly different to healthy controls, with an odds ratio of 1.14 (0.70-1.85, *P* > 0.05). Conversely, Duggan *et al*[21], demonstrated a higher prevalence of vitamin D deficiency in CP compared to controls (*P* = 0.026), which independently predicted BMD. This finding was noted in the setting of a strong association with smoking and chronic inflammation, which could suggest that vitamin D deficiency may serve as a co-factor for developing bone disease. Thus, the true utility of measuring vitamin D levels in CP remains unclear. Further studies are needed to elucidate whether it accurately aids in the assessment of bone health in CP.

Vitamin K is another fat-soluble nutrient which plays a possible role in bone metabolism as a cofactor in several mechanisms, including gamma-carboxylation of osteocalcinin, inhibiting osteoclastogenesis and promoting osteoblastosis[39]. Vitamin K is deficient in 32%-63% of patients with CP[13,40]. In their P-Bone study, Stigliano *et al*[13] showed that serum vitamin K deficiency (< 0.2 ng/mL) was present in 32% of 211 CP patients studied, and associated with a higher risk of osteoporosis in male patients (OR 5.28; 95%CI: 1.31-2.14; *P* = 0.01). As this is the only study to date to have examined association of vitamin K deficiency in CP, further investigation is necessary to clarify its role in bone disease of CP. Currently, there are no recommendations to test for vitamin K deficiency in patients with CP, to help prevent bone disease.

***Alcohol***

Alcohol is a risk factor for osteoporosis in the general population, as it causes malnutrition and low BMI[41]. Several studies report an association between alcohol use in CP patients and fracture risk. In a large Veteran’s Administration study Munigala *et al*[42], compared two cohorts consisting of CP patients and controls (without history of bone disease or CP), with a primary outcome of fractures at any site. A higher prevalence for fractures was seen in patients with CP and alcohol use compared to the control cohort (OR = 2.30). Similar findings were reported in a retrospective Danish registry study, with an increased risk of fractures in patients with alcohol induced CP compared to non-alcohol CP (HR 2.0 *vs* 1.5; *P* < 0.0001)[43]. Interestingly, a similar association has not been directly found between alcohol use in CP and osteopenia or osteoporosis[36,44]. Alcohol cessation remains a priority recommendation by pancreas experts in patients with CP as a measure to reduce fracture risk[31-33].

***Tobacco***

Tobacco consumption has been associated with osteoporosis and fractures in the general population, irrespective of gender, and is also an independent risk factor for developing osteoporosis[45,46]. A few studies have analyzed the association in CP. In a cross sectional, match-controlled study, Duggan *et al*[28] reported low bone density scores among patients with the highest tobacco use. In a later study, the same group reported a strong association between heavy smoking and low vitamin D levels[21]. Munigala *et al*[42] also reported increased prevalence of fractures in smokers compared to non-smokers (OR = 1.97). Thus tobacco cessation is also recommended by pancreas experts to reduce the risk of bone disease in CP.

***Hypogonadism and opioid use***

A prospective, observational study by Gupta *et al*[47] demonstrated that up to 27% of non-menopausal patients with low BMD had hypogonadism. Chronic opioid use, suppresses the hypothalamic-pituitary-gonadal axis as well as the hypothalamic-pituitary-adrenal-axis resulting in opioid induced androgen deficiency which may predispose to osteopenia and osteoporosis[48]. There are no studies to determine if sex hormone replacement therapy in patients with CP has any benefits on bone density. In addition to opioids, CP patients should be queried about use of other medications that may cause bone loss such as steroids.

***Patients with multiple risk factors***

Patients with CP typically do not have isolated risk factors for bone disease; rather their health is compromised by multiple issues, all of which can contribute to the development of bone disease. In one study by Haas *et al*[15], higher bone density scores measured by dual-energy X-ray absorptiometry (DXA) were noted in patients with EPI who had received pancreatic enzyme replacement therapy. Hence it is possible that early correction of EPI in these patients can potentially prevent progression of bone disease. Additionally, population-based data that higher BMI is associated with decreased risk of osteoporosis was also seen in P-Bone trial by Stigliano (0.84 per unit; 0.76-0.94; *P* = 0.001), which further strengthens the argument that early diagnosis of malabsorption and EPI can be an effective strategy in reducing risk of bone disease in CP patients[13]. Further investigation with randomized trials would be warranted for more conclusive evidence to support this finding.

**FRACTURE RISK**

Fragility or low trauma fracture is the most consequential outcome of osteoporosis and is of particular concern for patients with CP. In 2010, a retrospective study examining the prevalence of fractures in patients with CP, noted that patients with CP have a higher risk of fracture when compared to those without CP and also patients with high risk gastrointestinal illnesses (*i.e.*, Crohn’s disease) (*P* < 0.0001)[49]. These findings were replicated in subsequent studies. In 2014 Bang *et al*[43] reported a fracture incidence rate of 42.9 per 1000 person years in CP *vs* 16.0 in the control group. In another retrospective analysis of the Veteran’s Administration database, a cohort of 3257 predominantly male patients was compared to a control group without CP[42]. They reported a higher OR of all fractures in CP (2.35; 95%CI: 2.00-2.77; *P* < 0.0001) with the highest prevalence of fractures noted in CP patients with a history of alcohol use, smoking or both.

**RECOMMENDATIONS**

Bone disease in CP can be attributed to several risk factors which act synergistically in propagating abnormal bone metabolism and increase the risk of fractures. Therefore, expert groups in the United States and also European society guidelines recommend instituting proactive measures in identifying at-risk patients, with the goal of addressing modifiable risk factors and also to reduce the risk of fractures[31-33]. In the United States, a multi-disciplinary CP working group recommended that all patients should have routine annual screening for nutrient deficiency irrespective of EPI[31]. If a diagnosis of EPI is determined, they also recommend supplementation of fat-soluble vitamins and nutrients. Furthermore, they recommend a baseline screening DXA scan in these patients with subsequent screening based on assessment of collective risk factors for fracture. European societal guidelines recommend that a baseline DXA scan should be extended to all patients with CP with follow up scans every 2 years if evidence for osteopenia is found. In addition, initiation of Vitamin D and calcium supplementation can help treat and prevent osteopenia, osteoporosis and lower the risk of fracture, thus patients with established bone disease should be thoroughly evaluated for appropriate therapies by an endocrinologist.

**REFERENCES**

1 **International Osteoporosis Foundation**. Facts and Statistics. Cited 30 December 2019 Available from: <https://www.iofbonehealth.org/facts-statistics>

2 **Somersalo A**, Paloneva J, Kautiainen H, LÖNnroos E, HEinÄNen M, Kiviranta I. Increased mortality after lower extremity fractures in patients <65 years of age. *Acta Orthop* 2016; **87**: 622-625 [PMID: 27615323 DOI: 10.1080/17453674.2016.1210533]

3 **Kanis JA**, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jönsson B. Intervention thresholds for osteoporosis in the UK. *Bone* 2005; **36**: 22-32 [PMID: 15663999 DOI: 10.1016/j.bone.2004.08.018]

4 **Astrand J**, Nilsson J, Thorngren KG. Screening for osteoporosis reduced new fracture incidence by almost half: a 6-year follow-up of 592 fracture patients from an osteoporosis screening program. *Acta Orthop* 2012; **83**: 661-665 [PMID: 23140108 DOI: 10.3109/17453674.2012.747922]

5 **Sambrook P**, Cooper C. Osteoporosis. *Lancet* 2006; **367**: 2010-2018 [PMID: 16782492 DOI: 10.1016/S0140-6736(06)68891-0]

6 **van Bodegraven AA**, Bravenboer N. Perspective on skeletal health in inflammatory bowel disease. *Osteoporos Int* 2020; **31**: 637-646 [PMID: 31822927 DOI: 10.1007/s00198-019-05234-w]

7 **Tilg H**, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. *Gut* 2008; **57**: 684-694 [PMID: 18408105 DOI: 10.1136/gut.2006.117382]

8 **Ali T**, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. *Am J Med* 2009; **122**: 599-604 [PMID: 19559158 DOI: 10.1016/j.amjmed.2009.01.022]

9 . American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. *Gastroenterology* 2003; **124**: 791-794 [PMID: 12612916 DOI: 10.1053/gast.2003.50107]

10 **Katz S**, Weinerman S. Osteoporosis and gastrointestinal disease. *Gastroenterol Hepatol (N Y)* 2010; **6**: 506-517 [PMID: 20978554]

11 **Danford CJ**, Trivedi HD, Bonder A. Bone Health in Patients With Liver Diseases. *J Clin Densitom* 2019 [PMID: 30744928 DOI: 10.1016/j.jocd.2019.01.004]

12 **Dujsikova H**, Dite P, Tomandl J, Sevcikova A, Precechtelova M. Occurrence of metabolic osteopathy in patients with chronic pancreatitis. *Pancreatology* 2008; **8**: 583-586 [PMID: 18824882 DOI: 10.1159/000159845]

13 **Stigliano S**, Waldthaler A, Martinez-Moneo E, Lionetto L, Robinson S, Malvik M, Hedstrom A, Kaczka A, Scholdei M, Haas S, Simmaco M, Delle Fave G, Lohr M, Simon P, Capurso G. Vitamins D and K as Factors Associated with Osteopathy in Chronic Pancreatitis: A Prospective Multicentre Study (P-BONE Study). *Clin Transl Gastroenterol* 2018; **9**: 197 [PMID: 30323223 DOI: 10.1038/s41424-018-0066-8]

14 **Duggan SN**, Smyth ND, Murphy A, Macnaughton D, O'Keefe SJ, Conlon KC. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014; **12**: 219-228 [PMID: 23856359 DOI: 10.1016/j.cgh.2013.06.016]

15 **Haas S**, Krins S, Knauerhase A, Löhr M. Altered bone metabolism and bone density in patients with chronic pancreatitis and pancreatic exocrine insufficiency. *JOP* 2015; **16**: 58-62 [PMID: 25640785 DOI: 10.6092/1590-8577/2898]

16 **Aubin JE**, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. *Osteoporos Int* 2000; **11**: 905-913 [PMID: 11193242 DOI: 10.1007/s001980070028]

17 **Ghishan FK**, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. *Am J Physiol Gastrointest Liver Physiol* 2011; **300**: G191-G201 [PMID: 21088237 DOI: 10.1152/ajpgi.00496.2010]

18 **Talukdar R**, Tandon RK. Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. *J Gastroenterol Hepatol* 2008; **23**: 34-41 [PMID: 17995943 DOI: 10.1111/j.1440-1746.2007.05206.x]

19 **Schett G**, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M, Oberhollenzer F, Lorenzini R, Redlich K, Axmann R, Zwerina J, Willeit J. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. *Arch Intern Med* 2006; **166**: 2495-2501 [PMID: 17159016 DOI: 10.1001/archinte.166.22.2495]

20 **Nakamura K**, Saito T, Kobayashi R, Oshiki R, Oyama M, Nishiwaki T, Nashimoto M, Tsuchiya Y. C-reactive protein predicts incident fracture in community-dwelling elderly Japanese women: the Muramatsu study. *Osteoporos Int* 2011; **22**: 2145-2150 [PMID: 20936400 DOI: 10.1007/s00198-010-1425-9]

21 **Duggan SN**, Purcell C, Kilbane M, O'Keane M, McKenna M, Gaffney P, Ridgway PF, Boran G, Conlon KC. An association between abnormal bone turnover, systemic inflammation, and osteoporosis in patients with chronic pancreatitis: a case-matched study. *Am J Gastroenterol* 2015; **110**: 336-345 [PMID: 25623657 DOI: 10.1038/ajg.2014.430]

22 **Palermo A**, Tuccinardi D, Defeudis G, Watanabe M, D'Onofrio L, Lauria Pantano A, Napoli N, Pozzilli P, Manfrini S. BMI and BMD: The Potential Interplay between Obesity and Bone Fragility. *Int J Environ Res Public Health* 2016; **13** [PMID: 27240395 DOI: 10.3390/ijerph13060544]

23 **Steer ML**, Waxman I, Freedman S. Chronic pancreatitis. *N Engl J Med* 1995; **332**: 1482-1490 [PMID: 7739686 DOI: 10.1056/NEJM199506013322206]

24 **Vaona B**, Armellini F, Bovo P, Rigo L, Zamboni M, Brunori MP, Dall'O E, Filippini M, Talamini G, Di Francesco V, Frulloni L, Micciolo R, Cavallini G. Food intake of patients with chronic pancreatitis after onset of the disease. *Am J Clin Nutr* 1997; **65**: 851-854 [PMID: 9062539 DOI: 10.1093/ajcn/65.3.851]

25 **Nicolás JM**, Estruch R, Antunez E, Sacanella E, Urbano-Márquez A. Nutritional status in chronically alcoholic men from the middle socioeconomic class and its relation to ethanol intake. *Alcohol Alcohol* 1993; **28**: 551-558 [PMID: 8274179 DOI: 10.1093/oxfordjournals.alcalc.a045432]

26 **Joshi A**, Reddy SV, Bhatia V, Choudhuri G, Singh RK, Singh N, Bhatia E. High prevalence of low bone mineral density in patients with tropical calcific pancreatitis. *Pancreas* 2011; **40**: 762-767 [PMID: 21441842 DOI: 10.1097/MPA.0b013e31821396b2]

27 **Sudeep K**, Chacko A, Thomas N, Selvakumar R, George B, Paul TV, Seshadri MS. Predictors of osteodystrophy in patients with chronic nonalcoholic pancreatitis with or without diabetes. *Endocr Pract* 2011; **17**: 897-905 [PMID: 21742614 DOI: 10.4158/EP10410.OR]

28 **Duggan SN**, O'Sullivan M, Hamilton S, Feehan SM, Ridgway PF, Conlon KC. Patients with chronic pancreatitis are at increased risk for osteoporosis. *Pancreas* 2012; **41**: 1119-1124 [PMID: 22836855 DOI: 10.1097/MPA.0b013e31824abb4d]

29 **Layer P**, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. *Gastroenterology* 1994; **107**: 1481-1487 [PMID: 7926511 DOI: 10.1016/0016-5085(94)90553-3]

30 **Struyvenberg MR**, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency - Breaking the myths. *BMC Med* 2017; **15**: 29 [PMID: 28183317 DOI: 10.1186/s12916-017-0783-y]

31 **Sheth SG**, Conwell DL, Whitcomb DC, Alsante M, Anderson MA, Barkin J, Brand R, Cote GA, Freedman SD, Gelrud A, Gorelick F, Lee LS, Morgan K, Pandol S, Singh VK, Yadav D, Wilcox CM, Hart PA. Academic Pancreas Centers of Excellence: Guidance from a multidisciplinary chronic pancreatitis working group at PancreasFest. *Pancreatology* 2017; **17**: 419-430 [PMID: 28268158 DOI: 10.1016/j.pan.2017.02.015]

32 **Dominguez-Munoz JE**, Drewes AM, Lindkvist B, Ewald N, Czakó L, Rosendahl J, Löhr JM; HaPanEU/UEG Working Group. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. *Pancreatology* 2018; **18**: 847-854 [PMID: 30344091 DOI: 10.1016/j.pan.2018.09.016]

33 **Forsmark CE**. Management of chronic pancreatitis. *Gastroenterology* 2013; **144**: 1282-91.e3 [PMID: 23622138 DOI: 10.1053/j.gastro.2013.02.008]

34 **Holick MF**. Vitamin D deficiency. *N Engl J Med* 2007; **357**: 266-281 [PMID: 17634462 DOI: 10.1056/NEJMra070553]

35 **Charoenngam N**, Shirvani A, Holick MF. Vitamin D for skeletal and non-skeletal health: What we should know. *J Clin Orthop Trauma* 2019; **10**: 1082-1093 [PMID: 31708633 DOI: 10.1016/j.jcot.2019.07.004]

36 **Morán CE**, Sosa EG, Martinez SM, Geldern P, Messina D, Russo A, Boerr L, Bai JC. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. *Am J Gastroenterol* 1997; **92**: 867-871 [PMID: 9149203]

37 **Haaber AB**, Rosenfalck AM, Hansen B, Hilsted J, Larsen S. Bone mineral metabolism, bone mineral density, and body composition in patients with chronic pancreatitis and pancreatic exocrine insufficiency. *Int J Pancreatol* 2000; **27**: 21-27 [PMID: 10811020 DOI: 10.1385/IJGC:27:1:21]

38 **Hoogenboom SA**, Lekkerkerker SJ, Fockens P, Boermeester MA, van Hooft JE. Systematic review and meta-analysis on the prevalence of vitamin D deficiency in patients with chronic pancreatitis. *Pancreatology* 2016; **16**: 800-806 [PMID: 27453461 DOI: 10.1016/j.pan.2016.07.010]

39 **Palermo A**, Tuccinardi D, D'Onofrio L, Watanabe M, Maggi D, Maurizi AR, Greto V, Buzzetti R, Napoli N, Pozzilli P, Manfrini S. Vitamin K and osteoporosis: Myth or reality? *Metabolism* 2017; **70**: 57-71 [PMID: 28403946 DOI: 10.1016/j.metabol.2017.01.032]

40 **Martínez-Moneo E**, Stigliano S, Hedström A, Kaczka A, Malvik M, Waldthaler A, Maisonneuve P, Simon P, Capurso G. Deficiency of fat-soluble vitamins in chronic pancreatitis: A systematic review and meta-analysis. *Pancreatology* 2016; **16**: 988-994 [PMID: 27681502 DOI: 10.1016/j.pan.2016.09.008]

41 **Cheraghi Z**, Doosti-Irani A, Almasi-Hashiani A, Baigi V, Mansournia N, Etminan M, Mansournia MA. The effect of alcohol on osteoporosis: A systematic review and meta-analysis. *Drug Alcohol Depend* 2019; **197**: 197-202 [PMID: 30844616 DOI: 10.1016/j.drugalcdep.2019.01.025]

42 **Munigala S**, Agarwal B, Gelrud A, Conwell DL. Chronic Pancreatitis and Fracture: A Retrospective, Population-Based Veterans Administration Study. *Pancreas* 2016; **45**: 355-361 [PMID: 26199986 DOI: 10.1097/MPA.0000000000000381]

43 **Bang UC**, Benfield T, Bendtsen F, Hyldstrup L, Beck Jensen JE. The risk of fractures among patients with cirrhosis or chronic pancreatitis. *Clin Gastroenterol Hepatol* 2014; **12**: 320-326 [PMID: 23644391 DOI: 10.1016/j.cgh.2013.04.031]

44 **Prabhakaran A**, Bhasin DK, Rana SS, Bhadada SK, Bhansali A, Rao C, Gupta R, Khandelwal N. Bone mineral metabolism and bone mineral density in alcohol related and idiopathic chronic pancreatitis. *Trop Gastroenterol* 2014; **35**: 107-112 [PMID: 25470873 DOI: 10.7869/tg.189]

45 **Korkor AB**, Eastwood D, Bretzmann C. Effects of gender, alcohol, smoking, and dairy consumption on bone mass in Wisconsin adolescents. *WMJ* 2009; **108**: 181-188 [PMID: 19753823]

46 **Bijelic R**, Milicevic S, Balaban J. Risk Factors for Osteoporosis in Postmenopausal Women. *Med Arch* 2017; **71**: 25-28 [PMID: 28428669 DOI: 10.5455/medarh.2017.71.25-28]

47 **Gupta N**, Singh S, Vargas L, Moore TE, Shostrom VK, Boerner BP. Prevalence of Low Bone Density and Comorbid Hypogonadism in Patients With Chronic Pancreatitis. *Pancreas* 2019; **48**: 387-395 [PMID: 30768576 DOI: 10.1097/MPA.0000000000001257]

48 **Gudin JA**, Laitman A, Nalamachu S. Opioid Related Endocrinopathy. *Pain Med* 2015; **16 Suppl 1**: S9-15 [PMID: 26461076 DOI: 10.1111/pme.12926]

49 **Tignor AS**, Wu BU, Whitlock TL, Lopez R, Repas K, Banks PA, Conwell D. High prevalence of low-trauma fracture in chronic pancreatitis. *Am J Gastroenterol* 2010; **105**: 2680-2686 [PMID: 20736937 DOI: 10.1038/ajg.2010.325]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 31, 2020

**First decision:** Februaey 28, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Balaban DV, Soares RLS **S-Editor:** Dou Y **L-Editor: E-Editor:**

**Table 1 Risk factors**

|  |  |
| --- | --- |
| **Modifiable risk factors contributing to bone disease in chronic pancreatitis** | **Proposed interventions** |
| Alcohol and tobacco | Counselling, abstinence |
| Nutritional deficiency | Replete vitamin D, calcium replacement |
| Body mass index | Address contributing factors: alcohol/tobacco use, enzyme replacement therapy, nutrition counselling |
| Exocrine insufficiency |
| Chronic opioid use and hypogonadism | Opioid sparing analgesia, early recognition |